Shopping Cart 0
Cart Subtotal
USD 0

North America Biosimilars Market 2021-2030 by Product Type (Non-glycosylated, Glycosylated), Indication (Cancer, Autoimmune Disease, Blood Disorder, Diabetes), Manufacturing (Contract, Inhouse), End User (Hospitals and Clinics, Research Institutes), and Country: Trend Forecast and Growth Opportunity

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 2700

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 4300

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 5800

Details

North America biosimilars market is expected to grow by 25.1% annually in the forecast period and reach USD 27.57 billion by 2030 driven by the affordability of biosimilar-based treatment, rising incidence of chronic diseases due to aging populations, patent expirations of many blockbuster drugs, and better healthcare provisions.

Highlighted with 29 tables and 54 figures, this 116-page report North America Biosimilars Market 2020-2030 by Product Type (Non-glycosylated, Glycosylated), Indication (Cancer, Autoimmune Disease, Blood Disorder, Diabetes), Manufacturing (Contract, Inhouse), End User (Hospitals and Clinics, Research Institutes), and Country: Trend Forecast and Growth Opportunity is based on a comprehensive research of the entire North America biosimilars market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2030 with 2019 as the base year (Year 2020 is not appropriate for research base due to the outbreak of COVID-19).

In-depth qualitative analyses include identification and investigation of the following aspects:

Market Structure

Growth Drivers

Restraints and Challenges

Emerging Product Trends & Market Opportunities

Porter's Fiver Forces

The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify North America biosimilars market in every aspect of the classification from perspectives of Product Type, Indication, Manufacturing, End User, and Country.

 

Based on Product Type, the North America market is segmented into the following sub-markets with annual revenue (USD mn) for 2019-2030 included in each section.

Recombinant Non-glycosylated Biosimilars

o Insulin

o Recombinant Human Growth Hormone (rHGH)

o Granulocyte Colony Stimulating Factor

o Interferon

Recombinant Glycosylated Biosimilars

o Monoclonal Antibodies (mAb)

o Erythropoietin (EPO)

o Follicle Stimulating Hormone

Recombinant Peptides and Others

o Tumor Necrosis Factor (TNF)-Inhibitor

o Parathyroid Hormone

o Enzymes, Immunomodulators, GnRH Analogs and Others

 

Based on Indication, the North America market is segmented into the following sub-markets with annual revenue (USD mn) for 2019-2030 included in each section.

Cancer

Autoimmune Disease

Blood Disorder

Diabetes

Growth Hormone Deficiency

Infectious Diseases

Other Indications

 

Based on Manufacturing, the North America market is segmented into the following sub-markets with annual revenue (USD mn) for 2019-2030 included in each section.

Contract Manufacturing

Inhouse Manufacturing

 

Based on End User, the North America market is segmented into the following sub-markets with annual revenue (USD mn) for 2019-2030 included in each section.

Hospitals and Clinics

Research Institutes

Other End Users

 

Geographically, the following national/local markets are fully investigated:

U.S.

Canada

Mexico

For each key country, detailed analysis and data for annual revenue (USD mn) are available for 2019-2030. The breakdown of key national markets by Product Type, Indication, and End User over the forecast years are also included.

 

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.

Key Players (this may not be a complete list and extra companies can be added upon request):

AMEGA Biotech S.A.

Apotex Inc.

Biocon Ltd

Biogen Inc.

Boehringer Ingelheim

Celltrion, Inc.

Dr. Reddy's Laboratories Ltd.

Eli Lilly and Company

Intas Pharmaceuticals Ltd.

LG Chem, Ltd.

Merck and Co. Inc.

Mylan N.V.

Pfizer Inc.

Samsung Biologics Co., Ltd.

Sandoz International GmbH

STADA Arzneimittel AG

Teva Pharmaceutical Industries Ltd.

(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

READ MORE

Table Of Content

Scope

1 Introduction 7

1.1 Industry Definition and Research Scope 7

1.1.1 Industry Definition 7

1.1.2 Research Scope 8

1.2 Research Methodology 11

1.2.1 Overview of Market Research Methodology 11

1.2.2 Market Assumption 12

1.2.3 Secondary Data 12

1.2.4 Primary Data 12

1.2.5 Data Filtration and Model Design 13

1.2.6 Market Size/Share Estimation 14

1.2.7 Research Limitations 15

1.3 Executive Summary 16

2 Market Overview and Dynamics 18

2.1 Market Size and Forecast 18

2.1.1 Impact of COVID-19 on World Economy 21

2.1.2 Impact of COVID-19 on the Market 24

2.2 Major Growth Drivers 26

2.3 Market Restraints and Challenges 31

2.4 Emerging Opportunities and Market Trends 34

2.5 Porter's Fiver Forces Analysis 38

3 Segmentation of North America Market by Product Type 42

3.1 Market Overview by Product Type 42

3.2 Recombinant Non-glycosylated Biosimilars 44

3.2.1 Insulin 46

3.2.2 Recombinant Human Growth Hormone (rHGH) 47

3.2.3 Granulocyte Colony Stimulating Factor 48

3.2.4 Interferon 49

3.3 Recombinant Glycosylated Biosimilars 50

3.3.1 Monoclonal Antibodies (mAb) 51

3.3.2 Erythropoietin (EPO) 52

3.3.3 Follicle Stimulating Hormone 53

3.4 Recombinant Peptides and Others 54

3.4.1 Tumor Necrosis Factor (TNF)-Inhibitor 55

3.4.2 Parathyroid Hormone 56

3.4.3 Enzymes, Immunomodulators, GnRH Analogs and Others 57

4 Segmentation of North America Market by Indication 58

4.1 Market Overview by Indication 58

4.2 Cancer 60

4.3 Autoimmune Disease 61

4.4 Blood Disorder 62

4.5 Diabetes 63

4.6 Growth Hormone Deficiency 64

4.7 Infectious Diseases 65

4.8 Other Indications 66

5 Segmentation of North America Market by Manufacturing 67

5.1 Market Overview by Manufacturing 67

5.2 Contract Manufacturing 69

5.3 Inhouse Manufacturing 70

6 Segmentation of North America Market by End User 71

6.1 Market Overview by End User 71

6.2 Hospitals and Clinics 73

6.3 Research Institutes 74

6.4 Other End Users 75

7 North America Market 2019-2030 by Country 76

7.1 Overview of North America Market 76

7.2 U.S. 79

7.3 Canada 89

7.4 Mexico 91

8 Competitive Landscape 93

8.1 Overview of Key Vendors 93

8.2 New Product Launch, Partnership, Investment, and M&A 97

8.3 Company Profiles 98

AMEGA Biotech S.A. 98

Apotex Inc. 100

Biocon Ltd 101

Biogen Inc. 102

Boehringer Ingelheim 103

Celltrion, Inc. 104

Dr. Reddy's Laboratories Ltd. 105

Eli Lilly and Company 106

Intas Pharmaceuticals Ltd. 107

LG Chem, Ltd. 108

Merck and Co. Inc. 109

Mylan N.V. 110

Pfizer Inc. 111

Samsung Biologics Co., Ltd. 112

Sandoz International GmbH 113

STADA Arzneimittel AG 114

Teva Pharmaceutical Industries Ltd. 115

RELATED REPORTS 116


List Of Figure

List of Figures:

 

Figure 1. Research Method Flow Chart 11

Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 14

Figure 3. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030 16

Figure 4. North America Biosimilars Market, 2019-2030, USD mn 18

Figure 5. EMA and FDA Biosimilar Approvals, 2015 - 2019 19

Figure 6. EMA-approved Biosimilars Distribution by Reference Product and Therapeutic Area 19

Figure 7. FDA-approved Biosimilars Distribution by Reference Product and Therapeutic Area 20

Figure 8. Impact of COVID-19 on Business 24

Figure 9. Primary Drivers and Impact Factors of North America Biosimilars Market 26

Figure 10. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million 29

Figure 11. World Population 65 and Over, % of Total Population, 1950-2060 29

Figure 12. Primary Restraints and Impact Factors of North America Biosimilars Market 31

Figure 13. Investment Opportunity Analysis 35

Figure 14. Porter's Fiver Forces Analysis of North America Biosimilars Market 38

Figure 15. Breakdown of North America Biosimilars Market by Product Type, 2019-2030, % of Revenue 43

Figure 16. North America Addressable Market Cap in 2021-2030 by Product Type, Value (USD mn) and Share (%) 43

Figure 17. North America Biosimilars Market by Product Type: Recombinant Non-glycosylated Biosimilars, 2019-2030, USD mn 44

Figure 18. North America Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Insulin, 2019-2030, USD mn 46

Figure 19. North America Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Recombinant Human Growth Hormone (rHGH), 2019-2030, USD mn 47

Figure 20. North America Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Granulocyte Colony Stimulating Factor, 2019-2030, USD mn 48

Figure 21. North America Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Interferon, 2019-2030, USD mn 49

Figure 22. North America Biosimilars Market by Product Type: Recombinant Glycosylated Biosimilars, 2019-2030, USD mn 50

Figure 23. North America Biosimilars Market by Recombinant Glycosylated Biosimilars: Monoclonal Antibodies (mAb), 2019-2030, USD mn 51

Figure 24. North America Biosimilars Market by Recombinant Glycosylated Biosimilars: Erythropoietin (EPO), 2019-2030, USD mn 52

Figure 25. North America Biosimilars Market by Recombinant Glycosylated Biosimilars: Follicle Stimulating Hormone, 2019-2030, USD mn 53

Figure 26. North America Biosimilars Market by Product Type: Recombinant Peptides and Others, 2019-2030, USD mn 54

Figure 27. North America Biosimilars Market by Recombinant Peptides and Others: Tumor Necrosis Factor (TNF)-Inhibitor, 2019-2030, USD mn 55

Figure 28. North America Biosimilars Market by Recombinant Peptides and Others: Parathyroid Hormone, 2019-2030, USD mn 56

Figure 29. North America Biosimilars Market by Recombinant Peptides and Others: Enzymes, Immunomodulators, GnRH Analogs and Others, 2019-2030, USD mn 57

Figure 30. Breakdown of North America Biosimilars Market by Indication, 2019-2030, % of Sales Revenue 59

Figure 31. North America Addressable Market Cap in 2021-2030 by Indication, Value (USD mn) and Share (%) 59

Figure 32. North America Biosimilars Market by Indication: Cancer, 2019-2030, USD mn 60

Figure 33. North America Biosimilars Market by Indication: Autoimmune Disease, 2019-2030, USD mn 61

Figure 34. North America Biosimilars Market by Indication: Blood Disorder, 2019-2030, USD mn 62

Figure 35. North America Biosimilars Market by Indication: Diabetes, 2019-2030, USD mn 63

Figure 36. North America Biosimilars Market by Indication: Growth Hormone Deficiency, 2019-2030, USD mn 64

Figure 37. North America Biosimilars Market by Indication: Infectious Diseases, 2019-2030, USD mn 65

Figure 38. North America Biosimilars Market by Indication: Other Indications, 2019-2030, USD mn 66

Figure 39. Breakdown of North America Biosimilars Market by Manufacturing, 2019-2030, % of Sales Revenue 68

Figure 40. North America Addressable Market Cap in 2021-2030 by Manufacturing, Value (USD mn) and Share (%) 68

Figure 41. North America Biosimilars Market by Manufacturing: Contract Manufacturing, 2019-2030, USD mn 69

Figure 42. North America Biosimilars Market by Manufacturing: Inhouse Manufacturing, 2019-2030, USD mn 70

Figure 43. Breakdown of North America Biosimilars Market by End User, 2019-2030, % of Revenue 72

Figure 44. North America Addressable Market Cap in 2021-2030 by End User, Value (USD mn) and Share (%) 72

Figure 45. North America Biosimilars Market by End User: Hospitals and Clinics, 2019-2030, USD mn 73

Figure 46. North America Biosimilars Market by End User: Research Institutes, 2019-2030, USD mn 74

Figure 47. North America Biosimilars Market by End User: Other End Users, 2019-2030, USD mn 75

Figure 48. Breakdown of North America Biosimilars Market by Country, 2019 and 2030, % of Revenue 77

Figure 49. Contribution to North America 2021-2030 Cumulative Market by Country, Value (USD mn) and Share (%) 78

Figure 50. U.S. Biosimilars Market, 2019-2030, USD mn 80

Figure 51. Biosimilar Approvals and Launches in U.S., 2015-2020 80

Figure 52. Canada Biosimilars Market, 2019-2030, USD mn 89

Figure 53. Biosimilars Market in Mexico, 2019-2030, USD mn 91

Figure 54. Growth Stage of North America Biosimilars Industry over the Forecast Period 93


List Of Table

List of Tables:

 

Table 1. Snapshot of North America Biosimilars Market in Balanced Perspective, 2019-2030 17

Table 2. Growth Rate of World GDP, 2020-2022 22

Table 3. World Health Spending by Region, USD bn, 2013-2020 30

Table 4. Main Product Trends and Market Opportunities in North America Biosimilars Market 34

Table 5. North America Biosimilars Market by Product Type, 2019-2030, USD mn 42

Table 6. North America Biosimilars Market: Recombinant Non-glycosylated Biosimilars by Product, 2019-2030, USD mn 45

Table 7. North America Biosimilars Market: Recombinant Glycosylated Biosimilars by Product, 2019-2030, USD mn 50

Table 8. North America Biosimilars Market: Recombinant Peptides and Others by Product, 2019-2030, USD mn 54

Table 9. North America Biosimilars Market by Indication, 2019-2030, USD mn 58

Table 10. North America Biosimilars Market by Manufacturing, 2019-2030, USD mn 67

Table 11. North America Biosimilars Market by End User, 2019-2030, USD mn 71

Table 12. North America Biosimilars Market by Country, 2019-2030, USD mn 77

Table 13. U.S. Biosimilars Market by Product Type, 2019-2030, USD mn 82

Table 14. U.S. Biosimilars Market by Indication, 2019-2030, USD mn 82

Table 15. U.S. Biosimilars Market by End User, 2019-2030, USD mn 82

Table 16. FDA Approved Biosimilars in U.S., 2015-2020 83

Table 17. U.S. Select Pending Biosimilar BLAs as of December 2020 87

Table 18. U.S. Biosimilar Market Share (market share data through July 2020) 88

Table 19. Canada Biosimilars Market by Product Type, 2019-2030, USD mn 90

Table 20. Canada Biosimilars Market by Indication, 2019-2030, USD mn 90

Table 21. Canada Biosimilars Market by End User, 2019-2030, USD mn 90

Table 22. Mexico Biosimilars Market by Product Type, 2019-2030, USD mn 92

Table 23. Mexico Biosimilars Market by Indication, 2019-2030, USD mn 92

Table 24. Mexico Biosimilars Market by End User, 2019-2030, USD mn 92

Table 25. Breakdown of World Market by Key Vendor, 2020, % 95

Table 26. AMEGA Biotech S.A.: Company Snapshot 98

Table 27. AMEGA Biotech S.A.: Business Segmentation 98

Table 28. AMEGA Biotech S.A.: Product Portfolio 99

Table 29. AMEGA Biotech S.A.: Revenue, 2018-2020, USD mn 99

Licence Rights

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies


Companies

Key Players (this may not be a complete list and extra companies can be added upon request):

AMEGA Biotech S.A.

Apotex Inc.

Biocon Ltd

Biogen Inc.

Boehringer Ingelheim

Celltrion, Inc.

Dr. Reddy's Laboratories Ltd.

Eli Lilly and Company

Intas Pharmaceuticals Ltd.

LG Chem, Ltd.

Merck and Co. Inc.

Mylan N.V.

Pfizer Inc.

Samsung Biologics Co., Ltd.

Sandoz International GmbH

STADA Arzneimittel AG

Teva Pharmaceutical Industries Ltd.

(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Company Profile

Company Profile Title

North America biosimilars market is expected to grow by 25.1% annually in the forecast period and reach USD 27.57 billion by 2030 driven by the affordability of biosimilar-based treatment, rising incidence of chronic diseases due to aging populations, patent expirations of many blockbuster drugs, and better healthcare provisions.

Highlighted with 29 tables and 54 figures, this 116-page report North America Biosimilars Market 2020-2030 by Product Type (Non-glycosylated, Glycosylated), Indication (Cancer, Autoimmune Disease, Blood Disorder, Diabetes), Manufacturing (Contract, Inhouse), End User (Hospitals and Clinics, Research Institutes), and Country: Trend Forecast and Growth Opportunity is based on a comprehensive research of the entire North America biosimilars market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2030 with 2019 as the base year (Year 2020 is not appropriate for research base due to the outbreak of COVID-19).

In-depth qualitative analyses include identification and investigation of the following aspects:

Market Structure

Growth Drivers

Restraints and Challenges

Emerging Product Trends & Market Opportunities

Porter's Fiver Forces

The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify North America biosimilars market in every aspect of the classification from perspectives of Product Type, Indication, Manufacturing, End User, and Country.

 

Based on Product Type, the North America market is segmented into the following sub-markets with annual revenue (USD mn) for 2019-2030 included in each section.

Recombinant Non-glycosylated Biosimilars

o Insulin

o Recombinant Human Growth Hormone (rHGH)

o Granulocyte Colony Stimulating Factor

o Interferon

Recombinant Glycosylated Biosimilars

o Monoclonal Antibodies (mAb)

o Erythropoietin (EPO)

o Follicle Stimulating Hormone

Recombinant Peptides and Others

o Tumor Necrosis Factor (TNF)-Inhibitor

o Parathyroid Hormone

o Enzymes, Immunomodulators, GnRH Analogs and Others

 

Based on Indication, the North America market is segmented into the following sub-markets with annual revenue (USD mn) for 2019-2030 included in each section.

Cancer

Autoimmune Disease

Blood Disorder

Diabetes

Growth Hormone Deficiency

Infectious Diseases

Other Indications

 

Based on Manufacturing, the North America market is segmented into the following sub-markets with annual revenue (USD mn) for 2019-2030 included in each section.

Contract Manufacturing

Inhouse Manufacturing

 

Based on End User, the North America market is segmented into the following sub-markets with annual revenue (USD mn) for 2019-2030 included in each section.

Hospitals and Clinics

Research Institutes

Other End Users

 

Geographically, the following national/local markets are fully investigated:

U.S.

Canada

Mexico

For each key country, detailed analysis and data for annual revenue (USD mn) are available for 2019-2030. The breakdown of key national markets by Product Type, Indication, and End User over the forecast years are also included.

 

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.

Key Players (this may not be a complete list and extra companies can be added upon request):

AMEGA Biotech S.A.

Apotex Inc.

Biocon Ltd

Biogen Inc.

Boehringer Ingelheim

Celltrion, Inc.

Dr. Reddy's Laboratories Ltd.

Eli Lilly and Company

Intas Pharmaceuticals Ltd.

LG Chem, Ltd.

Merck and Co. Inc.

Mylan N.V.

Pfizer Inc.

Samsung Biologics Co., Ltd.

Sandoz International GmbH

STADA Arzneimittel AG

Teva Pharmaceutical Industries Ltd.

(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

READ MORE

Scope

1 Introduction 7

1.1 Industry Definition and Research Scope 7

1.1.1 Industry Definition 7

1.1.2 Research Scope 8

1.2 Research Methodology 11

1.2.1 Overview of Market Research Methodology 11

1.2.2 Market Assumption 12

1.2.3 Secondary Data 12

1.2.4 Primary Data 12

1.2.5 Data Filtration and Model Design 13

1.2.6 Market Size/Share Estimation 14

1.2.7 Research Limitations 15

1.3 Executive Summary 16

2 Market Overview and Dynamics 18

2.1 Market Size and Forecast 18

2.1.1 Impact of COVID-19 on World Economy 21

2.1.2 Impact of COVID-19 on the Market 24

2.2 Major Growth Drivers 26

2.3 Market Restraints and Challenges 31

2.4 Emerging Opportunities and Market Trends 34

2.5 Porter's Fiver Forces Analysis 38

3 Segmentation of North America Market by Product Type 42

3.1 Market Overview by Product Type 42

3.2 Recombinant Non-glycosylated Biosimilars 44

3.2.1 Insulin 46

3.2.2 Recombinant Human Growth Hormone (rHGH) 47

3.2.3 Granulocyte Colony Stimulating Factor 48

3.2.4 Interferon 49

3.3 Recombinant Glycosylated Biosimilars 50

3.3.1 Monoclonal Antibodies (mAb) 51

3.3.2 Erythropoietin (EPO) 52

3.3.3 Follicle Stimulating Hormone 53

3.4 Recombinant Peptides and Others 54

3.4.1 Tumor Necrosis Factor (TNF)-Inhibitor 55

3.4.2 Parathyroid Hormone 56

3.4.3 Enzymes, Immunomodulators, GnRH Analogs and Others 57

4 Segmentation of North America Market by Indication 58

4.1 Market Overview by Indication 58

4.2 Cancer 60

4.3 Autoimmune Disease 61

4.4 Blood Disorder 62

4.5 Diabetes 63

4.6 Growth Hormone Deficiency 64

4.7 Infectious Diseases 65

4.8 Other Indications 66

5 Segmentation of North America Market by Manufacturing 67

5.1 Market Overview by Manufacturing 67

5.2 Contract Manufacturing 69

5.3 Inhouse Manufacturing 70

6 Segmentation of North America Market by End User 71

6.1 Market Overview by End User 71

6.2 Hospitals and Clinics 73

6.3 Research Institutes 74

6.4 Other End Users 75

7 North America Market 2019-2030 by Country 76

7.1 Overview of North America Market 76

7.2 U.S. 79

7.3 Canada 89

7.4 Mexico 91

8 Competitive Landscape 93

8.1 Overview of Key Vendors 93

8.2 New Product Launch, Partnership, Investment, and M&A 97

8.3 Company Profiles 98

AMEGA Biotech S.A. 98

Apotex Inc. 100

Biocon Ltd 101

Biogen Inc. 102

Boehringer Ingelheim 103

Celltrion, Inc. 104

Dr. Reddy's Laboratories Ltd. 105

Eli Lilly and Company 106

Intas Pharmaceuticals Ltd. 107

LG Chem, Ltd. 108

Merck and Co. Inc. 109

Mylan N.V. 110

Pfizer Inc. 111

Samsung Biologics Co., Ltd. 112

Sandoz International GmbH 113

STADA Arzneimittel AG 114

Teva Pharmaceutical Industries Ltd. 115

RELATED REPORTS 116


List Of Figure

List of Figures:

 

Figure 1. Research Method Flow Chart 11

Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 14

Figure 3. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030 16

Figure 4. North America Biosimilars Market, 2019-2030, USD mn 18

Figure 5. EMA and FDA Biosimilar Approvals, 2015 - 2019 19

Figure 6. EMA-approved Biosimilars Distribution by Reference Product and Therapeutic Area 19

Figure 7. FDA-approved Biosimilars Distribution by Reference Product and Therapeutic Area 20

Figure 8. Impact of COVID-19 on Business 24

Figure 9. Primary Drivers and Impact Factors of North America Biosimilars Market 26

Figure 10. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million 29

Figure 11. World Population 65 and Over, % of Total Population, 1950-2060 29

Figure 12. Primary Restraints and Impact Factors of North America Biosimilars Market 31

Figure 13. Investment Opportunity Analysis 35

Figure 14. Porter's Fiver Forces Analysis of North America Biosimilars Market 38

Figure 15. Breakdown of North America Biosimilars Market by Product Type, 2019-2030, % of Revenue 43

Figure 16. North America Addressable Market Cap in 2021-2030 by Product Type, Value (USD mn) and Share (%) 43

Figure 17. North America Biosimilars Market by Product Type: Recombinant Non-glycosylated Biosimilars, 2019-2030, USD mn 44

Figure 18. North America Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Insulin, 2019-2030, USD mn 46

Figure 19. North America Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Recombinant Human Growth Hormone (rHGH), 2019-2030, USD mn 47

Figure 20. North America Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Granulocyte Colony Stimulating Factor, 2019-2030, USD mn 48

Figure 21. North America Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Interferon, 2019-2030, USD mn 49

Figure 22. North America Biosimilars Market by Product Type: Recombinant Glycosylated Biosimilars, 2019-2030, USD mn 50

Figure 23. North America Biosimilars Market by Recombinant Glycosylated Biosimilars: Monoclonal Antibodies (mAb), 2019-2030, USD mn 51

Figure 24. North America Biosimilars Market by Recombinant Glycosylated Biosimilars: Erythropoietin (EPO), 2019-2030, USD mn 52

Figure 25. North America Biosimilars Market by Recombinant Glycosylated Biosimilars: Follicle Stimulating Hormone, 2019-2030, USD mn 53

Figure 26. North America Biosimilars Market by Product Type: Recombinant Peptides and Others, 2019-2030, USD mn 54

Figure 27. North America Biosimilars Market by Recombinant Peptides and Others: Tumor Necrosis Factor (TNF)-Inhibitor, 2019-2030, USD mn 55

Figure 28. North America Biosimilars Market by Recombinant Peptides and Others: Parathyroid Hormone, 2019-2030, USD mn 56

Figure 29. North America Biosimilars Market by Recombinant Peptides and Others: Enzymes, Immunomodulators, GnRH Analogs and Others, 2019-2030, USD mn 57

Figure 30. Breakdown of North America Biosimilars Market by Indication, 2019-2030, % of Sales Revenue 59

Figure 31. North America Addressable Market Cap in 2021-2030 by Indication, Value (USD mn) and Share (%) 59

Figure 32. North America Biosimilars Market by Indication: Cancer, 2019-2030, USD mn 60

Figure 33. North America Biosimilars Market by Indication: Autoimmune Disease, 2019-2030, USD mn 61

Figure 34. North America Biosimilars Market by Indication: Blood Disorder, 2019-2030, USD mn 62

Figure 35. North America Biosimilars Market by Indication: Diabetes, 2019-2030, USD mn 63

Figure 36. North America Biosimilars Market by Indication: Growth Hormone Deficiency, 2019-2030, USD mn 64

Figure 37. North America Biosimilars Market by Indication: Infectious Diseases, 2019-2030, USD mn 65

Figure 38. North America Biosimilars Market by Indication: Other Indications, 2019-2030, USD mn 66

Figure 39. Breakdown of North America Biosimilars Market by Manufacturing, 2019-2030, % of Sales Revenue 68

Figure 40. North America Addressable Market Cap in 2021-2030 by Manufacturing, Value (USD mn) and Share (%) 68

Figure 41. North America Biosimilars Market by Manufacturing: Contract Manufacturing, 2019-2030, USD mn 69

Figure 42. North America Biosimilars Market by Manufacturing: Inhouse Manufacturing, 2019-2030, USD mn 70

Figure 43. Breakdown of North America Biosimilars Market by End User, 2019-2030, % of Revenue 72

Figure 44. North America Addressable Market Cap in 2021-2030 by End User, Value (USD mn) and Share (%) 72

Figure 45. North America Biosimilars Market by End User: Hospitals and Clinics, 2019-2030, USD mn 73

Figure 46. North America Biosimilars Market by End User: Research Institutes, 2019-2030, USD mn 74

Figure 47. North America Biosimilars Market by End User: Other End Users, 2019-2030, USD mn 75

Figure 48. Breakdown of North America Biosimilars Market by Country, 2019 and 2030, % of Revenue 77

Figure 49. Contribution to North America 2021-2030 Cumulative Market by Country, Value (USD mn) and Share (%) 78

Figure 50. U.S. Biosimilars Market, 2019-2030, USD mn 80

Figure 51. Biosimilar Approvals and Launches in U.S., 2015-2020 80

Figure 52. Canada Biosimilars Market, 2019-2030, USD mn 89

Figure 53. Biosimilars Market in Mexico, 2019-2030, USD mn 91

Figure 54. Growth Stage of North America Biosimilars Industry over the Forecast Period 93


List Of Table

List of Tables:

 

Table 1. Snapshot of North America Biosimilars Market in Balanced Perspective, 2019-2030 17

Table 2. Growth Rate of World GDP, 2020-2022 22

Table 3. World Health Spending by Region, USD bn, 2013-2020 30

Table 4. Main Product Trends and Market Opportunities in North America Biosimilars Market 34

Table 5. North America Biosimilars Market by Product Type, 2019-2030, USD mn 42

Table 6. North America Biosimilars Market: Recombinant Non-glycosylated Biosimilars by Product, 2019-2030, USD mn 45

Table 7. North America Biosimilars Market: Recombinant Glycosylated Biosimilars by Product, 2019-2030, USD mn 50

Table 8. North America Biosimilars Market: Recombinant Peptides and Others by Product, 2019-2030, USD mn 54

Table 9. North America Biosimilars Market by Indication, 2019-2030, USD mn 58

Table 10. North America Biosimilars Market by Manufacturing, 2019-2030, USD mn 67

Table 11. North America Biosimilars Market by End User, 2019-2030, USD mn 71

Table 12. North America Biosimilars Market by Country, 2019-2030, USD mn 77

Table 13. U.S. Biosimilars Market by Product Type, 2019-2030, USD mn 82

Table 14. U.S. Biosimilars Market by Indication, 2019-2030, USD mn 82

Table 15. U.S. Biosimilars Market by End User, 2019-2030, USD mn 82

Table 16. FDA Approved Biosimilars in U.S., 2015-2020 83

Table 17. U.S. Select Pending Biosimilar BLAs as of December 2020 87

Table 18. U.S. Biosimilar Market Share (market share data through July 2020) 88

Table 19. Canada Biosimilars Market by Product Type, 2019-2030, USD mn 90

Table 20. Canada Biosimilars Market by Indication, 2019-2030, USD mn 90

Table 21. Canada Biosimilars Market by End User, 2019-2030, USD mn 90

Table 22. Mexico Biosimilars Market by Product Type, 2019-2030, USD mn 92

Table 23. Mexico Biosimilars Market by Indication, 2019-2030, USD mn 92

Table 24. Mexico Biosimilars Market by End User, 2019-2030, USD mn 92

Table 25. Breakdown of World Market by Key Vendor, 2020, % 95

Table 26. AMEGA Biotech S.A.: Company Snapshot 98

Table 27. AMEGA Biotech S.A.: Business Segmentation 98

Table 28. AMEGA Biotech S.A.: Product Portfolio 99

Table 29. AMEGA Biotech S.A.: Revenue, 2018-2020, USD mn 99

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS


Companies

Key Players (this may not be a complete list and extra companies can be added upon request):

AMEGA Biotech S.A.

Apotex Inc.

Biocon Ltd

Biogen Inc.

Boehringer Ingelheim

Celltrion, Inc.

Dr. Reddy's Laboratories Ltd.

Eli Lilly and Company

Intas Pharmaceuticals Ltd.

LG Chem, Ltd.

Merck and Co. Inc.

Mylan N.V.

Pfizer Inc.

Samsung Biologics Co., Ltd.

Sandoz International GmbH

STADA Arzneimittel AG

Teva Pharmaceutical Industries Ltd.

(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)